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Despite significant efforts over the last several 
decades, treating patients with severe condi-
tions of myocardial ischemia and peripheral 
vascular disease remains challenging. For 
example, critical limb ischemia, a severe 
form of peripheral vascular disease, can lead 
to a 50% risk of amputation [1] with high 
incidences of second-leg loss and mortality 
within 2–5 years after the first amputation. 
Pathophysiologically, the main cause of these 
clinical entities is the loss or dysfunction of 
blood vessels, of which the major component 
is endothelial cells (ECs). Thus, therapeutic 
neovascularization has emerged as an attrac-
tive approach to re-establish functional vas-
culature, which can support proper blood 
perfusion and tissue repair [2].
Among several available modalities, cell-
based therapy has garnered much attention 
as it can potentially supply functional ECs to 
form new blood vessels. Particularly, autolo-
gous ECs are in high demand, but their avail-
ability is limited. To resolve this problem, EC 
generation via adult stem or progenitor cells, 
such as endothelial progenitor cells, mesenchy-
mal stem cells or bone marrow mononuclear 
cells, was attempted with limited success. It 
turned out that they work mainly through 
paracrine effects and even those effects were 
still modest [3–6]. More recently, human pluri-
potent stem cells (PSCs) including embryonic 
stem cells and induced pluripotent stem cells 
(iPSCs) were used for generating ECs. While 
PSC-derived ECs have shown potent vessel-
forming effects, they have limitations for clini-
cal use due to ethical issues (in case of embry-
onic stem cells), potential side effects such as 
tumorigenicity/aberrant tissue formation [7,8], 
lengthy and complex differentiation processes, 
low differentiation efficiency and difficulties 
in maintaining the phenotype [9,10].
Recently, a series of studies has reported a 
new method called direct reprogramming (or 
direct conversion or transdifferentiation) of 
somatic cells into specific lineage cells, such as 
ECs, neurons, cardiomyocytes or hepatocytes, 
using lineage or cell type-specific transcription 
factors or miRNAs without first dedifferentiat-
ing into a pluripotent state [11]. This approach 
has received notable attention and is regarded 
as the third-generation modality for cell ther-
apy and regenerative medicine as it can reduce 
not only the time and cost of target cell gen-
eration, but also the potential side effects and 
inefficiency associated with the use of adult or 
PSCs mentioned above. Accordingly, this edi-
torial will briefly review the progress of direct 
reprogramming of somatic cells into ECs.
Reprogramming into ECs via partial 
pluripotency
Margariti et al. reported generation of ECs 
by reprogramming human fibroblasts (HFs) 
using iPSC-inducing factors (OCT4, SOX2, 
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KLF4 and c-MYC) and EC differentiation condi-
tion [12]. Short-term induction of iPSC-inducing fac-
tors altered the plasticity of HFs enough to generate 
partial-iPSCs, which were then differentiated into 
ECs under defined media and culture conditions. 
These ECs were referred to as partial-iPSCs–ECs. In 
line with these efforts, two other groups also reported 
reprogramming of HFs into ECs using iPSC-inducing 
factors [13,14]. By exposing HFs to these four iPSC-
inducing factors for 8 days, followed by culture in 
mesodermal induction media, angioblast-like progeni-
tor cells were obtained [13]. In this study, all four factors 
were necessary to convert HFs into the angioblast-like 
stage. Li et al. further optimized the process by using 
only two factors (OCT4 and KLF4) [14]. Although 
these methods may be considered as direct reprogram-
ming, they are not direct reprogramming in a strict 
sense because they first need to undergo dedifferentia-
tion processes to acquire partial pluripotency and then 
follow an endothelial differentiation pathway, which 
basically mimics the differentiation process from 
PSCs. While these methods are valuable to expedite 
the process of generating ECs, there remain concerns 
about tumorigenesis due to the use of iPSC-inducing 
factors. In addition, other concerns related to human 
PSC-derived ECs mentioned above still remain.
Direct reprogramming of somatic cells into 
ECs
To achieve true ‘direct reprogramming’ of somatic cells 
into ECs by bypassing stem-cell-like stages, investiga-
tors attempted EC-lineage-specific transcription fac-
tors. Ginsberg et al. reported generation of ECs by direct 
reprogramming from human amniotic cells (ACs) 
using lentiviral ETS transcription factors (ETV2, FLI1 
and ERG1) along with a TGFβ inhibitor, and these 
expandable ECs were referred to as reprogrammed 
AC vascular endothelial cells (rAC-VECs) [10]. This 
combination of short-term TGFβ inhibition, transient 
ETV2 expression and continuous expression of FLI1 
and ERG1 were required for the transition from ACs 
to rAC-VECs. rAC-VECs were shown to have simi-
lar transcriptome to human umbilical vein endothelial 
cells. They also demonstrated that rAC-VECs formed 
tubes in vitro and in vivo with Matrigel, and were 
engrafted into the blood vessels in regenerating liver 
suggesting the capability of establishing functional 
vessels. The authors acknowledged that ETV2 expres-
sion alone was insufficient to turn on all EC genes, and 
an attempt at using human postnatal cells as a source 
cells was unsuccessful. Additionally, due to the origin 
of source cells, it is not clear if the source cells were fully 
differentiated and if there is potential contamination 
with stem or progenitor cells. The authors suggested 
that this study did not aim to achieve autologous cell 
therapy, but allogenic cell therapy using banked ACs. 
Nonetheless, this report was the first study demon-
strating feasibility of cellular reprogramming into ECs 
with EC-specific transcription factors. Two years later, 
Han et al. directly converted adult mouse skin fibro-
blasts into ECs, referred to as induced ECs (iECs), by 
using five transcription factors (Foxo1, Etv2, Klf2, Tal1 
and Lmo2) in lentiviral vector [15]. They observed that 
all five factors were required for efficient reprogram-
ming into iECs (Tie2-GFP+ 4%) and ETV2 alone was 
insufficient for successful reprogramming of mouse 
skin fibroblasts.
More recently, studies have shown successful repro-
gramming of postnatal HFs into ECs [16,17]. Morita et al. 
reported that the single-factor ETV2, which is transduced 
in doxycycline-inducible lentiviral vector, could directly 
convert HFs into ECs, referred to as ETV2-induced 
vascular endothelial cells (ETVECs) [16]. ETVECs 
are a proliferative CD31high (PECAM1high) cell popula-
tion selectively sorted at 15 days (CD31+ 3.5%) after 
ETV2 overexpression and displayed endothelial pheno-
type in vitro. The authors demonstrated that ETVECs 
implanted with Matrigel promoted blood flow recovery 
in ischemic hindlimb of non-obsese diabetic/severe 
combined immunodeficiency (NOD SCID) mice, and 
were engrafted into blood vessels in vivo. However, dur-
ing the culture period of more than 50 days, ETVECs 
maintained high expression of ETV2, which should 
be minimally expressed in any mammalian postnatal 
ECs. Therefore, it can be argued that ETVECs are not 
reprogrammed or iECs but rather selected cells display-
ing the ectopic expression of CD31 (PECAM1), which 
is one of the direct targets of ETV2 [18]. We recently 
reported that overexpression of ETV2 alone via doxy-
cycline-inducible lentiviral vector directly reprogramed 
HFs into ECs through at least two distinct stages [17]. 
At the early stage of reprogramming, KDR+ cells sorted 
at day 7 after ETV2 transduction displayed less mature 
but enriched endothelial characteristics. These cells 
were termed early reprogrammed ECs (rECs). Implan-
tation of early rECs into ischemic hindlimbs demon-
strated incorporation of rECs into the functional vessels, 
enhanced neovascularization and repaired tissue isch-
emia, indicating its functional and therapeutic poten-
tial. These early rECs were further cultured in vitro for 
another 2 months after transient reinduction of ETV2 
for 7 days. These rECs showed reduced ETV2 expres-
sion, increased PECAM1 expression (as well as all other 
“The use of lentiviral vectors raises safety issues 
as it may induce insertional mutagenesis, possible 
generation of replication competent lentiviruses and 
germline transfer.”
www.futuremedicine.com 319future science group
Direct reprogramming into endothelial cells: a new source for vascular regeneration    Editorial
EC proteins such as CDH5 [or VE-CADHERIN] and 
VWF), a transcriptome profile similar to human umbil-
ical vein endothelial cells and NO production, indicat-
ing a mature EC phenotype and were thus referred to 
as late rECs. These late rECs also showed the capability 
of incorporation into vessels in vivo. This study clearly 
demonstrated that ETV2 alone can directly reprogram 
HFs into ECs, which have several phenotypes, and can 
be applied for cell therapy.
There is another approach modulating a signaling 
pathway of innate immunity to trigger cellular repro-
gramming. Sayed et al. reported a new method to 
directly convert HFs using polyinosinic:polycytidylic 
acid into ECs, which was referred to as iECs [19]. 
Polyinosinic:polycytidylic acid activated toll-like 
receptor 3, which consequently induced global changes 
in the expression and activity of epigenetic modifiers. 
Such enhanced epigenetic plasticity together with ECs 
transdifferentiation culture conditions induced the 
conversion of HFs into iECs. Flow cytometry revealed 
2% of induced HFs expressed PECAM1 when 8-Br-
cAMP was added for enhancing the transdifferen-
tiation efficiency. In a mouse model of hindlimb isch-
emia, transplantation of iECs increased blood flow 
and capillary density without incorporation of iECs 
into the microvasculature, suggesting that therapeu-
tic potential of iECs is mainly attributed to paracrine 
effects. Although this method has a clear advantage of 
avoiding genetic manipulation, concerns were raised 
against the failure to incorporate into the vasculature 
and the low reprogramming efficiency.
Conclusion & future perspective
Ground-breaking discovery has been made in the repro-
gramming of human somatic cells into ECs. Overex-
pression of several key genes including ETV2 and small 
molecules were found to induce changes in somatic cell 
identity into ECs. This novel approach cannot only be 
used for cell therapy but also direct application of these 
reagents for in vivo regenerative therapy. In addition, the 
reprogrammed cells can be applied for disease investiga-
tion, drug discovery and precision medicine. However, 
questions remain to be answered. Particularly, the use of 
lentiviral vectors and the low reprogramming efficiency 
limit clinical application of the reprogrammed or iECs. 
The use of lentiviral vectors raises safety issues as it may 
induce insertional mutagenesis, possible generation of 
replication competent lentiviruses and germline trans-
fer. Thus, more clinically compatible materials should 
be developed such as adenoviral vectors, noncoding 
RNAs, exosomes and small molecules. Furthermore, 
the efficiency of direct reprogramming is low. When 
primary human somatic cells are used as source cells, 
the best efficiency is still less than 20% [13,16]. Particu-
larly, to enhance the reprogramming efficiency, studies 
for exploring the reprogramming mechanisms should 
follow. Deep sequencing of RNAs and bioinformatics 
will help identify factors that can facilitate and aug-
ment reprogramming. Furthermore, the phenotypes of 
induced or rECs were not meticulously addressed. The 
stages of rECs compared with the developmental stages 
and their arterial, venous and lymphatic phenotypes 
need to be addressed in future studies.
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